Lillian L. Siu

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group

L. Kvols, P. Poitras, D. Rayson, 2006, Current oncology.

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

W. Hayes, D. Nuyten, J. Marshall, 2011, British Journal of Cancer.

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.

G. Pond, A. Oza, D. Hedley, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

E. Eisenhauer, A. Oza, H. Hirte, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study.

H. Mackay, A. Oza, Z. Kassam, 2010, Current oncology.

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

E. Eisenhauer, H. Hirte, A. Razak, 2011, British Journal of Cancer.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

L. C. Chen, J. Baselga, D. Birle, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of the pan-Bcl2 family inhibitor GX15-070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas.

J. Marshall, L. Siu, J. Kuruvilla, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

L. Seymour, H. Hirte, L. Siu, 2014, British Journal of Cancer.